In patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes. These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy.
Wong et al. (Tue,) studied this question.